Logo

Invitrogen Inks Drug-Discovery Collaboration with Chinese Drug-Screening Concern

Oct 31, 2005

NEW YORK , Oct. 31 (GenomeWeb News) - Invitrogen will provide its drug-discovery technologies to the National Center for Drug Screening, a Shanghai-based public technology organization that specializes in screening new drugs in China, the company said today.

 

The deal calls for Invitrogen to contribute drug-discovery technologies such as GeneBlazer and Polar Screen, and to help the NationalCenter for Drug Screening develop new assays and techniques specific to the collaboration, the company said.

 

Specific terms of the arrangement were not disclosed.

Breaking News
The Scan

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.